No Data
Beijing Hotgen Biotech Co.,Ltd (688068.SH): Recently obtained 17 overseas qualification certifications.
Gelonghui, January 17 – Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that the company recently obtained 17 qualifications for Overseas certification. The acquisition of these qualifications has enriched the variety of products, further improved the menu of the company's in vitro diagnostic products, while actively responding to the demands of overseas markets, facilitating the company's ability to expand its market, and enhancing its core competitiveness.
Hejing Biotech: Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Results Forecast
Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Results Forecast
High R&D investment and a decline in the terminal hospitalization price of products have resulted in Beijing Hotgen Biotech Co., Ltd turning from profit to loss in 2024, with Q4 net profit decreasing almost fivefold year-on-year.
① Regarding the main reasons for the decline in performance, Beijing Hotgen Biotech Co.,Ltd attributes it to high R&D investment, intensified competition in the Industry, and increased R&D investment from joint ventures. ② As medical centralized procurement continues to advance, competition within the Industry intensifies, leading to further declines in the terminal hospitalization prices of products, and Beijing Hotgen Biotech Co.,Ltd's single machine revenue and output rate have shown varying degrees of decline.
Beijing Hotgen Biotech Co., Ltd (688068.SH): Expected net loss in 2024 is between 0.175 billion yuan and -0.2 billion yuan.
On January 14, Gelonghui reported that Beijing Hotgen Biotech Co., Ltd (688068.SH) announced preliminary estimates from the finance department, expecting annual revenue in 2024 to be between 490 million yuan and 520 million yuan, which represents a year-on-year decrease of 3.93% to 9.47% compared to the same period last year (legally disclosed data). It is expected that the net income attributable to shareholders of the parent company in 2024 will be between -175 million yuan and -200 million yuan. This will result in a loss compared to the same period last year. It is expected that the net income attributable to shareholders of the parent company, after deducting non-recurring gains and losses, will be between -240 million yuan and.
Beijing Hotgen Biotech Co., Ltd (688068.SH): First repurchase of 0.4952 million shares of the company.
On January 8, Gronghui announced that Beijing Hotgen Biotech Co.,Ltd (688068.SH) disclosed that on January 7, 2025, the company initially repurchased 495,201 shares of stock through the centralized bidding trading system of the Shanghai Exchange, accounting for 0.535% of the company's total share capital of 92,474,692 shares. The highest price for the repurchase was 75 yuan/share, the lowest price was 70.23 yuan/share, and the total amount of funds paid was 36,164,305.45 yuan (excluding stamp duty, trading commissions, and other transaction fees).